These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 9596985)
1. [Advances in the study of pharmacogenetics in China in 1996]. Xie H; Zhou H Zhonghua Yi Xue Za Zhi; 1997 Jan; 77(1):77-8. PubMed ID: 9596985 [No Abstract] [Full Text] [Related]
7. Detection of CYP2C19 alleles *1, *2 and *3 by multiplex polymerase chain reaction. Griese EU; Läpple F; Eichelbaum M Pharmacogenetics; 1999 Jun; 9(3):389-91. PubMed ID: 10471071 [No Abstract] [Full Text] [Related]
8. [Status of pharmacogenomics and its future role in drug therapy]. Cascorbi I Internist (Berl); 2002 Apr; 43(4):506-10. PubMed ID: 12053407 [No Abstract] [Full Text] [Related]
9. High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. Kaneko A; Lum JK; Yaviong L; Takahashi N; Ishizaki T; Bertilsson L; Kobayakawa T; Björkman A Pharmacogenetics; 1999 Oct; 9(5):581-90. PubMed ID: 10591538 [TBL] [Abstract][Full Text] [Related]
10. Association of polymorphisms in the cytochrome P450 (CYP) 2C19 and 2C18 genes in Japanese epileptic patients. Mamiya K; Ieiri I; Miyahara S; Imai J; Furuumi H; Fukumaki Y; Ninomiya H; Tashiro N; Yamada H; Higuchi S Pharmacogenetics; 1998 Feb; 8(1):87-90. PubMed ID: 9511186 [No Abstract] [Full Text] [Related]
11. How to correctly calculate the proportions of the heterozygotes and homozygotes in the extensive metabolizers of a certain drug-metabolizing enzyme in an ethnic or racial population? Xie HG Clin Pharmacol Ther; 1998 Nov; 64(5):575. PubMed ID: 9834051 [No Abstract] [Full Text] [Related]
12. High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu. Kaneko A; Kaneko O; Taleo G; Björkman A; Kobayakawa T Lancet; 1997 Mar; 349(9056):921-2. PubMed ID: 9093256 [No Abstract] [Full Text] [Related]
13. Pharmacogenetics and psychopharmacotherapy. Poolsup N; Li Wan Po A; Knight TL J Clin Pharm Ther; 2000 Jun; 25(3):197-220. PubMed ID: 10886465 [TBL] [Abstract][Full Text] [Related]
14. Frequencies of defective CYP2C19 alleles in a Hong Kong Chinese population: detection of the rare allele CYP2C19*4. Garcia-Barceló M; Chow LY; Kum Chiu HF; Wing YK; Shing Lee DT; Lam KL; Waye MM Clin Chem; 1999 Dec; 45(12):2273-4. PubMed ID: 10585366 [No Abstract] [Full Text] [Related]
15. Pharmacogenetics of CYP2C subfamily in a Japanese population. Ieiri I; Higuchi S J Toxicol Sci; 1998 Jul; 23 Suppl 2():129-31. PubMed ID: 9760448 [No Abstract] [Full Text] [Related]
16. The relationship between phenytoin pharmacokinetics and the CYP2C19 genotype in Japanese epileptic patients. Watanabe M; Iwahashi K; Kugoh T; Suwaki H Clin Neuropharmacol; 1998; 21(2):122-6. PubMed ID: 9579299 [TBL] [Abstract][Full Text] [Related]
17. Drug metabolism and variability among patients in drug response. Wilkinson GR N Engl J Med; 2005 May; 352(21):2211-21. PubMed ID: 15917386 [No Abstract] [Full Text] [Related]
18. Pharmacogenetics: role in modifying drug dosage regimens. Mah JT; Wong JY; Lee EJ Ann Acad Med Singap; 2000 Sep; 29(5):628-32. PubMed ID: 11126699 [TBL] [Abstract][Full Text] [Related]
19. Identification of the highly polymorphic S-mephenytoin hydroxylase in humans. Soucek P; Guo Z; Sandhu P; Martin MV; Cosme J; Beaune PH; Guengerich FP Arch Toxicol Suppl; 1996; 18():437. PubMed ID: 8678819 [No Abstract] [Full Text] [Related]